The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Expansion Is Expected For The Corifact Market Over The Forecast Period?
Historical expansion was driven by the identification of fibrinogen deficiency, progress in trauma treatment, enhanced protocols for managing surgical bleeding, regulatory approvals for plasma-derived therapies, and widespread acceptance by hospitals.
Growth in the forecast period is projected to stem from an increase in emergency surgical procedures, the evolving demands of an aging demographic, the expansion of trauma care facilities, improvements in coagulation diagnostics, and a heightened need for rapid hemostatic agents. Simultaneously, key trends anticipated for this period encompass the expanded application of fibrinogen concentrates, an intensified focus on swift bleeding management, the broadening of trauma and surgical care services, the implementation of hospital-based hemostasis management strategies, and rising adoption in the treatment of liver diseases.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp
What Influential Factors Are Boosting The Corifact Market Demand?
The corifact market is anticipated to expand due to the rising occurrence of bleeding disorders, which are conditions that hinder the blood’s proper clotting, causing excessive or extended bleeding. The escalation in these disorders stems from enhanced diagnosis, greater public awareness, breakthroughs in genetic testing, along with shifts in lifestyle and the presence of underlying health issues. Corifact addresses bleeding disorders resulting from factor XIII deficiency by supplying the absent clotting factor, thereby aiding in the formation of stable blood clots and diminishing excessive bleeding. For example, a December 2023 report from the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), a UK-based entity, highlighted the impact of bleeding disorders in 2023/24, noting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, in addition to 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the growing prevalence of bleeding disorders is fueling the growth of the corifact market. The corifract market is projected to grow due to the increasing demand for biological products, which are intricate pharmaceutical agents sourced from living organisms for diagnosing, preventing, treating, and curing various diseases and medical ailments. This increased demand for biological products is linked to heightened environmental concerns, greater consumer understanding, and the necessity for sustainable and efficient alternatives to man-made chemicals. Corifract aids biological products by improving their stability, bioavailability, and effectiveness, thereby guaranteeing peak performance and extended shelf life through advanced formulation and delivery methods. For example, in August 2025, the Assistant Secretary for Planning and Evaluation, a US government department, reported that biosimilar net revenue could range from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger markets, with proposed regulatory adjustments such as universal interchangeability, a global comparator, and the elimination of comparative efficacy studies expected to reduce development costs and increase lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Thus, the growing demand for biological products is propelling the corifract market.
Which Segment Groups Define The Corifact Market Landscape?
The corifact market covered in this report is segmented –
1) By Product: Human-Derived Factor XIII, Recombinant Factor XII
2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management
3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics
Who Are The Firms Contributing To The Corifact Market Ecosystem?
Major companies operating in the corifact market are CSL Behring
Access The Complete Corifact Market Report:
https://www.thebusinessresearchcompany.com/report/corifact-global-market-report
Which Region Is The Primary Market For The Corifact Market?
North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model